O que ADARx Pharmaceuticals, Inc. divulgou em 12 de novembro de 2026
Do próprio 8-K da empresa.
O que a direção disse
“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline,”
Citado literalmente da divulgação, e mostrado apenas quando o documento atribui a fala a uma pessoa com nome.
O que ADARx Pharmaceuticals, Inc. faz
ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation RNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable small interfering RNA (“siRNA”) therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. ADARx’s three hepatic-targeted programs are agazisiran, onvuzosiran and ADX-626, and its two extrahepatic-targeted programs are ADX-077 and ADX-199. Beyond its named programs, ADARx plans to continue to leverage its proprietary technologies to strategically expand its pipeline of next-generation siRNA therapeutics. ADARx’s goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.
A descrição da própria empresa, como aparece no rodapé da divulgação.
The quote, the company description and the latest quarter come from ADARx Pharmaceuticals’s earnings press release (an Item 2.02 8-K) filed 12 de novembro de 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Ler a divulgação no EDGAR As cotações são ajustadas por desdobramentos e dividendos.
